ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
ORL@Cu-MOF Boost Cuproptosis and Suppress Fatty Acid Metabolism for Cancer Lymph Node Metastasis Synergistic Therapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Amplifying bacterial cuproptosis by NIR driven biomimetic metal organic framework for nanocatalytic enhanced bacterial pneumonia immunotherapy.Bioactive materials · 2026Article
- Cuproptosis and ferroptosis: signal pathways, diseases and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Self-assembled nano-PROTACs potentiate colorectal cancer immunotherapy via downregulating PD-L1 and GPX4 expression.Materials today. Bio · 2026Article
- PEG-GE11-modified nanoplatform for co-delivery of cisplatin and plumbagin in targeted therapy of oral squamous cell carcinoma.RSC advances · 2026Article
- Copper homeostasis and cuproptosis rewire the tumor microenvironment: mechanisms, immune modulation, and therapeutic opportunities.Journal of hematology & oncology · 2026Review
- Advances and Prospects in MOF-Based Platforms for Tumor Hyperthermia.Bioengineering (Basel, Switzerland) · 2026Review
- Metal-dependent regulated cell death: Molecular architecture and translational frontiers.iMeta · 2026Review
- Cuproptosis-based nanomedicine in cancer metastasis synergistic therapy.Acta pharmaceutica Sinica. B · 2026Review
- Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Harnessing Cuproptosis resistance to advance cancer therapeutics.Apoptosis : an international journal on programmed cell death · 2026Review
- From molecular crosstalk to precision therapy: targeting ferroptosis and cuproptosis in oral squamous cell carcinoma.Frontiers in oncology · 2026Review
- Dual-Metal Organic Framework Nanozyme for Synergistic Photothermal-Chemodynamic Therapy: Copper-Molybdenum Synergism in Gastric Cancer Treatment.International journal of nanomedicine · 2026Article
- Targeting lung cancer: synergistic therapeutic strategy of cuproptosis and immunogenic cell death.Frontiers in cell and developmental biology · 2026Review
- Orlistat: a comprehensive review of a lipase inhibitor from obesity management to emerging oncological applications.Frontiers in pharmacology · 2026Review
- Neutrophil Extracellular Trap Reprograms Cancer Metabolism to Form a Metastatic Niche Promoting Non-Small Cell Lung Cancer Brain Metastasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Epigenetic Reprogramming of Erythroid Progenitor Cells: Insights for Enhancing Cancer Immunotherapy.International journal of biological sciences · 2026Review
- From Barrier to Gateway: Nanomaterials Reshaping the Tumor Microenvironment for Therapy.International journal of nanomedicine · 2026Review
- Advanced nanotechnology in enhancing immune checkpoint inhibitors (ICIs) for head and neck cancer therapy.Cell communication and signaling : CCS · 2025Review
- Metabolic cell deaths in head and neck cancer: mechanisms, therapeutic potential, and challenges.Annals of medicine · 2025Review
- The importance of specificity of drug treatment in head and neck cancer: current developments in personalized medicine to improve safety and tolerability.Expert review of clinical pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Lymph node metastasis (LNM) is one of the significant characteristics of poor prognosis in oral squamous cell carcinoma (OSCC), strongly associated with high mortality rates. Immunotherapy has emerged as a crucial treatment modality for OSCC LNM, yet its limited response rate severely restricts its clinical application. Cuproptosis, a newly discovered immunogenic cell death (ICD), is often hindered by lipid metabolic reprogramming in tumor cells, which also contributes significantly to the lack of response to immunotherapy. Herein, a metal-organic framework (MOF) nanodrug loaded with orlistat (ORL) is developed, designated as ORL@Cu-MOF. This nanodrug is designed to respond and release under the high glutathione (GSH) stimulus of the tumor microenvironment (TME), thereby inducing cuproptosis and suppressing fatty acid metabolism in OSCC cells. In vivo, ORL@Cu-MOF effectively triggers cuproptosis and inhibits fatty acid metabolism, exerting antitumor effects in mouse models and remodeling the TME. Furthermore, the combination of ORL@Cu-MOF with programmed death receptor-1 (αPD-1) significantly enhances immunotherapy outcomes, transforming "cold tumors" into "hot tumors". This study is the first to report the synergistic use of cuproptosis induction and fatty acid metabolism suppression in the treatment of metastatic cancer, offering novel insights for the care and management of LNM of OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.